

ASX Announcement Change in Executive Remuneration

2 March 2018. Melbourne, Australia.

Rhinomed Limited (ASX: RNO or "the Company") engaged Crichton and Associates, remuneration consultants to review its remuneration policies and make recommendations on the Company's remuneration levels based on the market conditions and expectations.

Following the review, the Board is pleased to advise that the remuneration package including incentives has been agreed with the Company's Managing Director and Chief Executive Officer, Mr Michael Johnson.

The key terms and conditions of Michael's revised remuneration structure are outlined below:

| Terms | Details |
|---------------------------------|--|
| Start Date | 1 March 2018 |
| Total Fixed Remuneration | \$325,000 per annum including statutory superannuation. |
| Short Term Incentives | Bonus of \$150,000 including superannuation for the period ending 30 June 2018 subject to board satisfaction on the achievement in areas of: <ul style="list-style-type: none"> • Financial and distribution numbers – 50% weighting • Targeting product innovation – 15% weighting • Business development plan – 25% weighting • Operational excellence – 10% weighting |
| Long Term Incentives | 4 million options exercisable at 27 cents have previously been granted with shareholder approval. Eligibility to participate in the Company's ESOP subject to board discretion and shareholder approval. |
| Notice Period | 180 days |
| Term of Agreement | No Fixed Term |

All other terms and conditions remain the same.

...Ends...

Company Enquiries:

Michael Johnson, CEO & Director
+61 (0) 3 8416 0900
mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo @mutesnoring @theturbinecom